Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06450041
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-05-31
Brief Title:
NANT 2021-01 Phase II STING Sequential Temozolomide Irinotecan NK Cells and GD2 mAb Trial
Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Organization:
New Approaches to Neuroblastoma Therapy Consortium
Organization Data
Organization:
New Approaches to Neuroblastoma Therapy Consortium
Class:
OTHER
Study ID:
NANT 2021-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Nationwide Childrens Hospital | OTHER |
| United Therapeutics | INDUSTRY |
| Childrens Neuroblastoma Cancer Fund | UNKNOWN |